# Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

> **NCT01709513** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 314 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Atorvastatin
- **DRUG:** Ezetimibe
- **DRUG:** Alirocumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01709513
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-30
- **Primary completion:** 2014-05-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2020-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709513, "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01709513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*